Dive into the forefront of bioprocessing evolution this March, where our expert panel explores sustainability, bioseparations, and innovation in cell and gene therapy...
UK’s RoslinCT, a cell and gene therapy contract development and manufacturing organization, will be part of the Vertex Pharmaceuticals global network producing the CRISPR...
Alexion, AstraZeneca's rare disease division, has agreed to buy a portfolio of preclinical gene therapy programs and enabling technologies from competitor Pfizer for up...
Swiss CDMO Siegfried has acquired a 95% stake in Dinamiqs, a compatriot biotech focused on developing and manufacturing viral vectors for cell and gene therapies.
US-based Vertex Pharmaceuticals has agreed to pay $320 million in cash to acquire ViaCyte, a compatriot private cellular therapy company specializing in a treatment for...
Solvias, a Swiss CDMO serving the pharmaceutical, biotechnology, material science and cosmetic industries, has acquired Dutch biotech Cergentis for an undisclosed sum...
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...
Leading US gene therapy CDMO Catalent is buying all shares of another CDMO in the same field, plasmid DNA (pDNA) specialist’s Delphi Genetics, headquartered at Gosselie...
